Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06269055 · ClinicalTrials.gov registry record
Long-term Result of DTPA (Diethylenetriamine Pentaacetate) Chelation for Gadolinium Deposition Disease
A clinical trial of Gadolinium Deposition Disease and Ca-DTPA, sponsored by Stanford University.
- Recruiting
- Registry status
- 50
- Enrollment target
- 1
- Study location
NCT06269055: Recruiting study of Gadolinium Deposition Disease and Ca-DTPA, sponsored by Stanford University.
NCT06269055 is a study of Gadolinium Deposition Disease and Ca-DTPA that is actively recruiting participants, run by Stanford University. The registered enrollment target is 50 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06269055, a study of Gadolinium Deposition Disease and Ca-DTPA, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is aimed at describing the degree of benefit, if any, and the adverse effects, if any, from receiving 5 or more treatment sessions of Gadolinium Deposition Disease using two-day chelation treatment with the chelating agents Calcium Diethylenetriamine pentaacetate (Ca-DTPA) and Zinc Diethylenetriamine pentaacetate (Zn-DTPA).
Primary Outcome
Patient-completed data regarding symptoms experienced and their intensity when they began and currently, rated from 0 (none) to 5 (very severe). Outcome measure will be change in each symptom's intensity.
Conditions Studied
Interventions
- OTHER Interview
Study Locations (1)
California
- Stanford University Medical Center - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2024-12-02 |
| Est. Completion | 2026-05 |
What NCT06269055 shows while recruiting
NCT06269055 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target.
The record links to 2 conditions, with Gadolinium Deposition Disease appearing as the primary indexed condition, and to 1 intervention - of which Interview is the first listed.
NCT06269055 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06269055 about?
NCT06269055 is a clinical study titled "Long-term Result of DTPA (Diethylenetriamine Pentaacetate) Chelation for Gadolinium Deposition Disease". This study is aimed at describing the degree of benefit, if any, and the adverse effects, if any, from receiving 5 or more treatment sessions of Gadolinium Deposition Disease using two-day chelation treatment with the chelating agents Calcium Diethylenetriamine pentaacetate (Ca-DTPA) and Zinc Diethy...
What is the current status of trial NCT06269055?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2024-12-02. Estimated completion is 2026-05.
What conditions does trial NCT06269055 study?
This clinical trial studies the following conditions: Gadolinium Deposition Disease, Ca-DTPA.
What interventions are being tested in trial NCT06269055?
The interventions under investigation include: Interview (OTHER).
Who is sponsoring clinical trial NCT06269055?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06269055 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI